- Home
- ZG vs INCY Comparison
ZG vs INCY Comparison
Compare ZG & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- INCY
- Stock Information
- Founded
- ZG 2004
- INCY 1991
- Country
- ZG United States
- INCY United States
- Employees
- ZG N/A
- INCY N/A
- Industry
- ZG Business Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ZG Consumer Discretionary
- INCY Health Care
- Exchange
- ZG Nasdaq
- INCY Nasdaq
- Market Cap
- ZG 20.9B
- INCY 17.0B
- IPO Year
- ZG 2011
- INCY 1993
- Fundamental
- Price
- ZG $68.43
- INCY $106.46
- Analyst Decision
- ZG Buy
- INCY Buy
- Analyst Count
- ZG 31
- INCY 19
- Target Price
- ZG $86.67
- INCY $89.19
- AVG Volume (30 Days)
- ZG 640.1K
- INCY 2.8M
- Earning Date
- ZG 10-30-2025
- INCY 10-28-2025
- Dividend Yield
- ZG N/A
- INCY N/A
- EPS Growth
- ZG N/A
- INCY 3878.02
- EPS
- ZG N/A
- INCY 5.90
- Revenue
- ZG $2,483,000,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- ZG $17.58
- INCY $19.33
- Revenue Next Year
- ZG $14.15
- INCY $10.47
- P/E Ratio
- ZG N/A
- INCY $17.86
- Revenue Growth
- ZG 15.17
- INCY 18.09
- 52 Week Low
- ZG $56.63
- INCY $53.56
- 52 Week High
- ZG $90.22
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- ZG 40.09
- INCY 73.66
- Support Level
- ZG $68.35
- INCY $91.16
- Resistance Level
- ZG $72.10
- INCY $109.28
- Average True Range (ATR)
- ZG 2.24
- INCY 4.59
- MACD
- ZG -0.02
- INCY 0.64
- Stochastic Oscillator
- ZG 26.23
- INCY 89.25
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.